ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells-Reference-Cited by-同舟云学术

ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells

Published:2024-07-01 Issue:1 Volume:327 Page:C184-C192
ISSN:0363-6143
Container-title:American Journal of Physiology-Cell Physiology
language:en
Short-container-title:American Journal of Physiology-Cell Physiology

Author:

Nemethova Veronika¹²^ORCID,Babiakova Petra¹,Teglasova Boglarka¹,Uhelska Lucia¹,Babelova Andrea³⁴^ORCID,Selc Michal³⁴,Jakic Kristina³,Mitrovsky Ondrej⁵⁶,Myslivcova Denisa⁵,Zackova Marketa⁵⁷,Poturnayova Alexandra⁸,Batorova Angelika²⁹,Drgona Lubos¹⁰,Razga Filip¹²

Affiliation:

1. Selecta Biotech SE, Bratislava, Slovakia

2. Department of Hematology and Transfusiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia

3. Department of Nanobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia

4. Centre for Advanced Materials Application, Slovak Academy of Sciences, Bratislava, Slovakia

5. Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic

6. Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic

7. Department of Condensed Matter Physics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic

8. Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Bratislava, Slovakia

9. Department of Hematology and Transfusiology, Faculty of Medicine, Medical School Comenius University, Slovak Medical University, University Hospital, Bratislava, Slovakia

10. Department of Oncohematology, Comenius University and National Cancer Institute, Bratislava, Slovakia

Abstract

Effective treatment modalities targeting leukemic clones that escape tyrosine kinase inhibitor (TKI) therapy could be game changers in the professional management of patients displaying primary resistance, intolerance, or acquired resistance to TKIs. Although delivering authentic innovations today is more complex than ever, we developed a highly potent and safe oligonucleotide-based modality against BCR-ABL1 mRNA named ASP210 that effectively induces cell death in BCR-ABL1-positive TKI-resistant cells while sparing BCR-ABL1-negative healthy cells.

Funder

Agentúra na Podporu Výskumu a Vývoja

Ministerstvo Zdravotnictví Ceské Republiky

Slovenská Akadémia Vied

Vedecká Grantová Agentúra MŠVVaŠ SR a SAV

Publisher

American Physiological Society

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpcell.00188.2024

Reference22 articles.

1. The molecular biology of chronic myeloid leukemia

2. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

3. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

4. Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options

5. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias